# Bioequivalence - Duodart Against Avodart & Omnic

> **NCT01657851** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 35 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** dutasteride/tamsulosin
- **DRUG:** dutasteride
- **DRUG:** tamsulosin

## Key facts

- **NCT ID:** NCT01657851
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-23
- **Primary completion:** 2012-12-05
- **Final completion:** 2012-12-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01657851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01657851, "Bioequivalence - Duodart Against Avodart & Omnic". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01657851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*